This web site uses cookies. Do you accept the use of external cookies? Yes No Know more x
Survey about achondroplasia
We have designed a questionnaire with the purpose to better know the population connected to achondroplasia.
The questionnaire is optional and anonymous. The data obtained will be used for statistical purposes and to better understand the natural history of achondroplasia. Please consider answering.
If you would like to take the survey later, you can click on the link at the top "Register at BA"

Ascendis Pharma, the Denmark based emerging pharmaceutical company, shared the results on the Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 12 months in Prepubertal Children with Achondroplasia.


Important Information:

The company states that in this Phase 2 Trial, TransCon CNP demonstrated the potential to meet patient and caregiver needs for a safe, effective, tolerable, and convenient treatment. The primary endpoint, annualized height velocity (AHV) at Week 52, demonstrated superiority of TransCon CNP at 100 µg/kg/week compared to placebo (p=0.0218).

Furthermore, TransCon CNP was generally well tolerated with low frequency of injection site reactions, which allowed that all 57 randomized children stayed with the treatment beyond two years.

The data found showed important and consistent results across age groups and dose levels, supporting continued development with the selected dose of 100 µg/kg/week.

Read the official document here:

 
To view this site you need Internet Explorer 8 (or a higher version)
or another internet browser.


Thank You.